BCL2L1 and acute lymphoblastic leukemia: DT2216 selectively degraded Bcl-XL in MOLT-4 T-cell acute lymphoblastic leukemia (T-ALL) cells (DC50 = 0.063 μM, Dmax = 90.8%), while human platelets (DC50 > 3 μM, Dmax = 26%) are less affected [64].